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Reading Time: 10 minutes 
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INSTRUCTIONS TO CANDIDATES 
 
Answer questions in the spaces provided on this exam paper.  
There are two sections for this paper. 
Section A, Time: 48 minutes. Answer ALL multiple choice questions. 




You may begin writing from the commencement of the examination session.  The reading time 
indicated above is provided as a guide only. 
This is a CLOSED BOOK examination 
Any non-programmable calculator is permitted 
No handwritten notes are permitted 
Hard copy, unannotated English translation dictionary only 
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SECTION A 
 
INSTRUCTIONS FOR QUESTIONS 1 - 48 
Answer all questions by circling your answer (“A” to “E”) for each question. 
Each question is worth 1 mark and has only one correct response. 
















*** END OF SECTION A ***  
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INSTRUCTIONS FOR QUESTIONS 49 - 58 
Answer all questions in the space provided on this examination paper.  Each 
question specifies the number of marks for the question and, where 
appropriate, sub-questions.  Follow the instructions given in each question.  
 
This section is worth 60% (72 marks) of the examination. 
 
 
Question 49 [6 Marks] 
Answer BOTH parts: 
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(a) Sketch the up-curve using the data points provided and, showing your method on the 
graph, hence estimate: 
Bingham died stress: f = 
 





(b) Showing your working, calculate the “coefficient of plastic viscosity” for semisolid 
material X. 
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Question 50 [13 Marks] 
Accelerated stability testing is based upon the Arrhenius equations: 
𝑘𝑘 = 𝐴𝐴𝑒𝑒−𝐸𝐸𝑎𝑎𝑅𝑅𝑅𝑅 
where R = 8.314 J K-1 mol-1 
This is employed throughout the pharmaceutical industry.  Constructing an Arrhenius plot for 
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(a) Given 0 °C = 273.15 K, calculate T  at 25 °C and hence determine ln(k) (marking your 
method on the graph above) and the first-order rate constant k. [2 Marks] 











Ln(k) =   show your method on the graph 
k =   include the units 
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(b) Given the equation for first order decay is: 
𝐶𝐶𝑡𝑡 = 𝐶𝐶0𝑒𝑒−𝑘𝑘𝑡𝑡  
where k = first-order rate constant 
Showing your working, confirm that the half life of first-order kinetics is  
𝑡𝑡½ = 𝐿𝐿𝐿𝐿 (2)𝑘𝑘  






















The half life of the formulation at 25 °C is    
 
 
(c) Assuming the shelf life of the formulation is the time to 5 % degradation (95 % of 
original activity), showing your working, calculate the shelf life of the formulation at 
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(d) Calculate the gradient of the graph and hence the activation energy for the degradation 
















































(e) State whether the Ahrennius equation projection of shelf life is reliable for this drug 
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Question 51 [6 Marks] 
List THREE (3) physicochemical properties of a drug that must be considered when developing 
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Question 52 [6 Marks] 
Answer BOTH parts: 
The release of drug from an oral formulation is given below: 
Time (h) 0 1 2 4 6 
Cumulative release (%) 0 8.9 22.2 48.9 75.6 
 
(a) Complete the graph of cumulative drug release against time from the tabulated data 
above and, showing your method on the graph, determine the lag time of the 
absorption process. [5 Marks] 
 
The estimated lag time is:   .   hours. 
 
(b) State whether the device is controlled release or modified release and outline the reason 
for your answer: [1 Mark] 
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Question 53 [6 Marks] 
Epithelia demonstrate "polarity".  Explain how polarity is achieved using a suitable example. 
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Question 54 [8 Marks] 
Answer BOTH parts: 
Below is a diagram of a membrane moderated transdermal patch. 








(b) Explain the nature of the rate limiting step in the absorption process and the observed 
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Question 55 [10 Marks] 
Answer ALL parts: 
(a) Many formulations are either controlled release or modified release. With the aid of 
a suitable diagram of plasma concentration against time, define these terms and 
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(b) MR formulations release their drug content in two aliquots or portions (referred to as Di 
and Dm).  Explain why such a pattern of release is desirable and the rate-limiting step 
in the absorption of each aliquot.  Explain how multiple-unit membrane devices 
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Question 56 [6 Marks] 
For each of the epithelia shown in the diagrams below, identify the type, function and a 
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Question 57 [4 Marks] 
Answer BOTH parts: 
(a) Poor physical stability is a key issue of protein therapeutics.  Outline two (2) factors 























(b) Explain one (1) formulation strategy that can be used to increase the bioavailability of 
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Question 58 [7 Marks] 
Answer ALL parts: 
(a) Briefly explain the terms “dependent” and “independent” in relation to the filling of 


















(b) Briefly explain why conventional capsules may be less expensive to produce than an 


















(c) List two (2) excipients that may accompany the powdered drug in a hard gelatin 










*** END OF SECTION B *** 
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*** END OF EXAMINATION *** 
 
 
 
 
 
 
 
